Objectives: We examined the effect of sildenafil citrate on advanced glycation end products (AGEs)-induced soluble fms-like tyrosine kinase 1 (sFlt-1) release in JEG-3 choriocarcinoma cells. Methods: Cells were incubated with control bovine serum albumin (BSA) or AGEs-BSA, and expression of sFlt-1 mRNA and protein release was determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA), respectively. AGEs-BSA increased sFlt-1 mRNA expression and protein release in a dose-dependent manner. Results: Sildenafil citrate suppressed sFlt-1 mRNA expression and protein release in cells treated with AGEs-BSA in a dosedependent manner. Likewise, it inhibited the increase of reactive oxygen species (ROS) production and NF-κB activity in these cells. Cobalt protoporphyrin (CoPP) and bilirubin also inhibited sFlt-1 release and ROS production in cells treated with AGEs-BSA, whereas zinc protoporphyrin IX (ZnPP IX) antagonized the effect of sildenafil citrate. In cells transfected with the heme oxygenase-1 (HO-1) siRNA, sildenafil citrate failed to inhibit the sFlt-1 release and ROS production. 
Preeclampsia is one of the most common obstetrical complications affecting up to 8% of all gestations 1 and remains major causes of maternal and neonatal mortality and morbidity in Korea and worldwide. It typically presents after 20th week of gestation and is characterized by newonset hypertension with proteinuria and/or edema during pregnancy. 2 It is accepted that abnormal implantation of the blastocyst and abnormal placental bed remodeling or other causes of reduced placental perfusion are prerequisites for preeclampsia, 1 but the mechanistic links between this step and the development of preeclampsia are still largely unknown.
A number of molecular pathways have been suggested to be involved in the cascade from placental events to maternal dysfunction. One of them which has been the subject of intense research is the production of the soluble form of the vascular endothelial growth factor (VEGF) receptor-1.
The soluble VEGF receptor-1 is also denoted as soluble fms-like tyrosine kinase-1 (sFlt-1) as it belongs to fmsrelated tyrosine kinase family. 3 The proto-oncogene fms encodes the tyrosine kinase transmembrane receptor. It has been shown that sFlt-1 is produced in the placenta during preeclampsia and is found to be elevated in the circulation of preeclamptic women, often before the onset of maternal symptoms. 3, 4 In addition, numerous experimental models have demonstrated the implication of sFlt-1 overexpression in the development of preeclampsia. 5~8 In maternal circulation, sFlt-1 binds to free VEGF and placental growth factor (PlGF), sequestering and making them unavailable for proper signaling. 3 Advanced glycation end-products (AGEs) represent the molecular complexes generated as a result of non-enzymatic reactions of carbohydrates and oxidized lipid with proteins.
These reactions leads to irreversible cross-linking of proteins, and as a consequence, loss of protein structure and function. 9 Accumulation of AGEs contribute to diverse metabolic disorders such as diabetes, 10 obesity, 11 metabolic syndromes, 12 and polycystic ovary syndrome. 13 The women with such disorders, when in pregnancy, have a higher risk of preeclampsia. 1 Previous studies demonstrated that serum AGEs in preeclamptic women were significantly higher than in healthy women. 14, 15 Accumulation of AGEs may induce oxidative injury and vascular perturbation in placental bed, leading to preeclampsia. 16 A recent study demonstrated that
AGEs might contribute to the pathogenesis of preeclampsia by promoting sFlt-1 production in extravillous trophoblasts, implicating AGEs in a novel bridge between metabolic disorders and preeclampsia. 17 Sildenafil, a specific inhibitor of cyclic guanosine mono- 19~21 Animal studies with rat models of preeclampsia induced by NG-nitro-L-arginine methyl ester (L-NAME) treatment 22 and placental ischemia 23 showed that sildenafil treatment significantly reduced the preeclamptic signs and symptoms, such as hypertension, proteinuria and fetal mortality. Furthermore, sildenafil was shown to suppress elevation of the plasma levels of antiangiogenic factors including sFlt-1. 24 These results raised hope for the therapeutic potential of sildenafil as an effective option for the management of preeclampsia.
JEG-3, a choriocarcinoma cell line, may serve as an appropriate in vitro trophoblastic model to study preventive and therapeutic agents in the field of preeclampsia. 25 This could help to understand of the association between sFlt-1 and other gynecologic conditions such as endometriosis and menopause. 26 These cells have been shown to preserve responses to hypoxia to increase sFlt-1 mRNA expression and protein release. 27 In this study, we examined the effect of sildenafil on sFlt-1 release in the AGEs-treated JEG-3 cells, and evaluated the role of the heme oxygenase-1 (HO-1)
as a key molecule to mediate the action of sildenafil.
Materials and Methods 
Preparation of AGEs-BSA
AGEs-bovine serum albumin (AGEs-BSA) was prepared as previously described. 28 Endotoxin-free BSA (Calbiochem, La Jolla, CA, USA) of 5 g was incubated with 9 g D-glucose Table 1 .
ELISA
sFlt-1 protein was measured by ELISA by using Quantikine Human ELISA kit (R&D Systems, Minneapolis, MN, USA).
Analysis of intracellular reactive oxygen species (ROS) generation
The intracellular generation of ROS was measured 
Data analysis
Data were presented as means ± S.E. When necessary, the data were analyzed by one-way analysis of variance followed by Duncans multiple comparison test. A value of P < 0.05 was considered statistically significant. were 3.5 fold and 2.7 fold increases, respectively, in mRNA expression and protein release (Fig. 1 ).
To examine whether the effect of AGEs-BSA in this study resulted from interaction with RAGE, the effect of anti-RAGE antibody was determined. In the presence of anti- RAGE antibody, AGEs-BSA failed to increase the sFlt-1 mRNA expression and protein release, indicating that interaction with RAGE is essential for the process of cellular actions of AGEs-BSA (Fig. 2) .
Effect of AGEs-BSA on ROS production and NF-κB activity
Increased ROS production and NF-κ B activation has been shown to be implicated in the AGE-related pathophysiological processes. 29, 30 In significantly increased ROS production and NF-κ B activity. Anti-RAGE antibody inhibited the AGEs-BSA-induced stimulation of ROS production and NF-κ B activity (Fig. 3 ).
Inhibition of AGEs-BSA-induced cellular effects by sildenafil citrate
To determine the effect of sildenafil citrate on AGEs-
BSA-induced cellular effects, cells were incubated with
AGEs-BSA for 24 h in the presence of sildenafil citrate (Fig. 6 ).
Effects of HO-1 related molecules
In order to determine whether the effect of sildenafil (Fig. 8B, 8C ). These results confirm our hypothesis that upregulation of the HO-1 expression is the crucial mechanism to mediate the sildenafil citrate-induced inhibition of the sFlt-1 release and ROS production in cells treated with AGEs-BSA.
Discussion
Preeclampsia remains a major complication of pregnancy, affecting at least one out of twenty pregnancies. 1 Besides the risk for mother and fetus during pregnancy and delivery, preeclampsia also impacts long-term health. Systemic review and meta-analysis reported that women with preeclampsia are at two-fold increased risk of developing cardiovascular disorders in later life. 35 The later impact of preeclampsia is not confined to maternal health. It confers increased risk for cardiovascular complications to to the pathogenesis of preeclampsia. 17 In the present study we also observed that AGEs-BSA increased sFlt-1 mRNA expression and protein release (Fig. 1) . Although JEG-3 cells used in this study is a cell line established from choriocarcinoma, it has been shown to preserve trophoblastic cell-like characteristics, and might serve as an appropriate in vitro trophoblastic model for studies in various fields including preeclampsia. 25 Thus, the results in this study can give us a valuable insight into trophoblastic mechanism responsible for the pathophysiology of preeclampsia.
AGEs exert their cellular effects through the interaction with RAGE, AGE-R3 (galectin-3), and maybe other AGEbinding proteins. Among them, RAGE is the best characterized AGE receptor and responsible for most of the deleterious effects of AGEs, whereas AGE-R3 is probably implicated in the removal of AGEs. 37 In the presence of anti-RAGE antibody, AGEs-BSA did not affect the sFlt-1 mRNA expression and protein release, indicating that AGEs-RAGE interaction is essential for the process of cellular actions of AGEs-BSA (Fig. 2) . AGEs-BSA-induced increases in ROS production and NF-κ B activity are in accord with the previous understanding that increased ROS production and NF-κ B activation is implicated in the AGErelated pathophysiological processes. 29, 30 In the presence of anti-RAGE antibody, AGEs-BSA failed to stimulate ROS production and NF-κ B activity suggesting that these processes are also mediated through AGEs-RAGE interaction (Fig. 3) .
Management of preeclampsia is still restricted by a lack of effective therapeutic agents, and there has been interest in using PDE-5 inhibitors in this patient population. In the present study sildenafil citrate suppressed sFlt-1 mRNA expression and protein release in cells treated with AGEs-BSA in a dose-dependent manner (Fig. 4) . Likewise, it inhibited the increase of ROS production and NFkB activity in these cells (Fig. 5A , 5B). These observations could provide us with a new insight into pharmacological action of sildenafil citrate. In addition to its well-recognized vasodilatory effect, the therapeutic targets of sildenafil citrate for preeclampsia may be widened to include the mechanisms within trophoblastic cell per se. In this regard, a previous report is notable, which has shown that systemic administration of sildenafil to L-NAME treated preeclampsia model rats decreased the plasma levels of anti-angiogenic factors including sFlt-1. carbon monoxide (CO) and bilirubin. Bilirubin functions as a powerful antioxidant. 47, 48 As production of ROS has been known to be a major component of varied forms of hypertension, moderate increase in bilirubin could act to decrease overall oxidative stress. CO acts as a potent vasodilator, functioning in a manner similar to NO. 49 Of particular interest to preeclampsia, HO-1 and CO have been shown to directly inhibit production of VEGF and interferon-γ -induced secretion of sFlt-1.
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The present study strongly suggests the involvement of HO-1 in sildenafil citrate-induced inhibition of sFlt-1 release and ROS formation. qRT-PCR and Western blot analyses showed that sildenafil citrate upregulated the HO-1 expression (Fig. 6) . Furthermore, the HO-1 inducer CoPP 29 and metabolic product of HO-1 bilirubin 29 also inhibited sFlt-1 release and ROS production in cells treated with AGEs-BSA, whereas the HO-1 inhibitor ZnPP IX 29 antagonized the effect of sildenafil citrate (Fig. 7) . Finally, small interfering RNA approaches were used to confirm further the role of HO-1 in the action of sildenafil citrate. In cells transfected with the HO-1 siRNA, sildenafil citrate failed to inhibit the sFlt-1 release and ROS production (Fig. 8) . These results, taken together, strongly suggest that upregulation of the HO-1 expression is the crucial mechanism responsible for the sildenafil citrate-induced inhibition of the sFlt-1 release and ROS production in cells treated with AGEs-BSA.
